An Innovative New Cancer Drug and Delivery Platform

The SciTech Drug Delivery Platform (SDP)

  • Designed to safely deliver drugs.
  • Works by formulating drugs into very tiny spheres known as nanovesicles.
  • Nanovesicles “trick” cells into letting the drug inside.
  • Can be designed and engineered with other drugs providing more effective and patentable drugs.
  • May have the ability to be used as an adjunct to other therapies.
  • Cost-effective, scalable and biocompatible.
  • Potentially applicable to other modes of administration such as topical and oral.
The SciTech Drug Delivery platform creates nanovesicles, illustrated here, to better treat cancer.

Please visit for more detailed science information.

ST-001: A Breakthrough New Drug

About ST-001 nanoFenretinide

  • Our patented lead drug, ST-001 nanoFenretinide uses our Delivery Platform in combination with fenretinide, a drug with a well-documented safety profile.
  • ST-001 is administered to the patient intravenously (IV).
  • Once in the bloodstream, ST-001 nanovesicles bind to the cancer surface and penetrate the cell.
  • Once inside the cell, high concentrations of fenretinide are released which disrupts cellular DNA, causing the cancer cell to die.
A happy patient greets his doctor in the hospital.

ST-001 is Clinical Trial Ready

Our accelerated, Phase 1 clinical trial utilizes ST-001 nanoFenretinide for the treatment of T-cell lymphomas.
( Identifier: NCT04234048).

Our goal is to confirm that:

  • ST-001 nanoFenretinide new formulation is safe.
  • ST-001 nanovesicle platform can transport fenretinide into the cancer cell at the right dose and without toxic side effects.
  • ST-001 provides beneficial patient outcomes.

Fenretinide has also shown promise in the treatment of cervical, colorectal, head & neck, ovarian, pancreatic, prostate, and pediatric cancers.

SciTech's FDA approved, accelerated Clinical Trial Pathway.

Our Pipeline

SDP holds the promise of enhancing the therapeutic performance of other existing and future cancer and non-cancer drugs that have solubility and bioavailability challenges similar to those of fenretinide.

In addition to our initially targeted indications, we plan to pursue ST-001 nanoFenretinide for the treatment of:

  • Small cell lung cancer (SCLC)
  • Metastatic breast cancer (MBC)
  • Neuroblastoma (pediatric cancer)
  • T-cell acute lymphoblastic leukemia (T-ALL)
SciTech's Drug Development Pipeline.

For more detailed information on our science and our company, please visit